en داروسازي و فارماکولوژِی Pharmacology مروری Review <div style="text-align: justify;"><span style="font-size:12pt"><span new="" roman="" style="font-family:" times="">&nbsp; &nbsp;The global obesity epidemic, affecting approximately 890 million adults, has catalyzed substantial advances in pharmacological management. Contemporary anti-obesity medications, including GLP-1 receptor agonists, dual GLP-1/GIP agonists, lipase inhibitors, and combination neurochemical modulators, can achieve weight reductions ranging from 5% to 22%, thereby approaching outcomes that were previously attainable only through bariatric surgery. Notwithstanding these therapeutic gains, a pronounced gap persists between clinical capability and real-world accessibility, as many of these novel agents remain prohibitively expensive or unavailable across large regions.</span></span><br> <span style="font-size:12pt"><span new="" roman="" style="font-family:" times="">Within this context, Iran&rsquo;s pharmaceutical sector has demonstrated notable progress in the domestic production of several anti-obesity medications, including orlistat, marketed under more than 15 local brands, as well as metformin, liraglutide (Melitide, Maciza, Vikitide), tirzepatide (Spartina), and naltrexone/bupropion combinations (Lipoxon, Fandex). These developments have substantially enhanced treatment accessibility despite import restrictions and persistent cost barriers. However, rigorous head-to-head clinical trials comparing domestically manufactured products with their reference counterparts, alongside systematic post-marketing surveillance, remain indispensable for establishing long-term safety and therapeutic equivalence. In this regard, Iran&rsquo;s experience delineates a viable model for expanding global access to obesity pharmacotherapy through localized manufacturing, with significant implications for health equity.</span></span><br> &nbsp;</div> Obesity, Anti-obesity agents, Pharmacotherapy, Pharmaceutical manufacturing, Iran 94 96 http://jabs.fums.ac.ir/browse.php?a_code=A-10-1116-5&slc_lang=en&sid=1 Mojtaba Farjam مجتبی فرجام farjam.phd@gmail.com 100319475328460030978 100319475328460030978 No Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran مرکز تحقیقات بیماری‌های غیرواگیر، دانشگاه علوم پزشکی فسا، فسا، ایران Babak Pezeshki بابک پزشکی Mseif1364@gmail.com 100319475328460030979 100319475328460030979 No Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran مرکز تحقیقات بیماری‌های غیرواگیر، دانشگاه علوم پزشکی فسا، فسا، ایران Narges Fereydouni نرگس فریدونی narges.fereydouni2020@gmail.com 100319475328460030980 100319475328460030980 Yes Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran مرکز تحقیقات بیماری‌های غیرواگیر، دانشگاه علوم پزشکی فسا، فسا، ایران